In cancer, many aspects of the epigenome, controlled by DNA methylation, chromatin, and nucleosome positioning, are altered and an ever growing pipeline of agents targeting epigenetic regulation are under development and entering clinical trials.
Epigenetic Therapies in Oncology: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your epigentic drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.
Keeping you “In the know” Simply put, our mission is to fuel your knowledge of oncology, to make you the first to know about very early technologies and startups, emerging clinical trial results, drug approvals and the ever-changing competitive landscape. Epigenetic Therapies in Oncology: Analytical Tool achieves this by continuously scanning development in epigentic and reporting: * Deals & Collaborations * New technologies/drugs (emerging from patents, grants, abstracts (see Conference Coverage) etc.) * Funding/Grants/IPOs * Filings & Approvals * Latest Clinical Trial Development & Results * Newly launched clinical trials * Conference Coverage of the world’s twelve leading meetings in oncology* * Quarterly & Annual Reporting
This puts you in control of most, if not all, day-to-day developments in your field while also benefiting from one of the most comprehensive commercial pipeline review & competitive assessment tools available on the market today! Identify, prioritize, and lead scientific assessment of oncology opportunities and competition by multiple factors such as: * Emerging Technologies * Target Novelty * Recent Funding * Early & Late Stage Pipeline * Biomarker/Companion Diagnostic Development (featured below) * Entered Deals & Alliances * Conference surveillance of world leading cancer meetings (featured below) * Combination Therapy Choices (featured below) * Outcome of Clinical Trials * Indication Selection & Expansion Choices * Drug Repositioning Opportunities
For 20 years we have supported better decision making across the oncology drug development industry. Your Epigenetic Therapies in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computer’s desktop into a high capacity workbench within your area of choice. Even before launching this tool you have already eliminated the hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf.
Your Epigenetic Therapies in Oncology: Analytical Tool covers more than 111 companies plus partners who are today developing 221 epigentic drugs where of 148 are in active development in cancer across 62 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.
Let our expertise work for you With a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.
Your key to access development at the world-leading cancer meetings The Epigenetic Therapies in Oncology: Analytical Tool is continuously updated according to twelve of the world’s most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia). If you are not able to attend any of the conference(s) in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about.
Run combination therapy analysis like no other The Epigenetic Therapies in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.
Unparalleled biomarker surveillance We also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.
Support and inspiration at your finger-tips You also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.
A tool to grow with and keep you informed Unlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc. You can choose to renew your access to these updates and support on a yearly basis or go over to our industry leading full service platform covering all oncology drug development, 1stOncology.
System Requirements - Browser Application (Supports: Internet Explorer, FireFox, Chrome and Safari)) - Internet access
Our reports have been used by over 10K customers, including:
Biomarkers Market Size, Share & Trends Analysis Report By Type (Safety, Efficacy), By Application (Diagnostic, Drug Discovery & Development), By Disease (CVD, Cancer), By Region, And Segment Forecasts, 2021 - 2028 Biomarkers Market Growth & Trends The global biomarkers market size is expected...
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Adrenoleukodystrophy - Drugs In Development, 2021, provides an overview of the Adrenoleukodystrophy (Genetic Disorders) pipeline...
Pemphigus Vulgaris (Immunology) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Pemphigus Vulgaris - Drugs In Development, 2021, provides an overview of the Pemphigus Vulgaris (Immunology) pipeline landscape.Pemphigus vulgaris is a rare autoimmune...
Impetigo (Infectious Disease) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Impetigo - Drugs In Development, 2021, provides an overview of the Impetigo (Infectious Disease) pipeline landscape.Impetigo is a highly contagious skin condition. Impetigo...
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drugs in Development, 2021 Summary According to the recently published report ’Complement C5 - Drugs In Development, 2021’; Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or...
Ventricular Tachycardia (Cardiovascular) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Ventricular Tachycardia - Drugs In Development, 2021, provides an overview of the Ventricular Tachycardia (Cardiovascular) pipeline landscape.Ventricular...
Pompe Disease (Musculoskeletal) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Pompe Disease - Drugs In Development, 2021, provides an overview of the Pompe Disease (Metabolic Disorders) pipeline landscape.Pompe disease is an inherited disorder...
The medical device and diagnostics contract research organization market in Europe is expected to grow from US$ 4,060.41 million in 2021 to US$ 6,576.25 million by 2028; it is estimated to grow at a CAGR of 7.1% from 2021 to 2028. The CRO services industry is highly fragmented, with several hundred small and medium-sized limited-service...
The global eClinical Solutions market is projected to reach USD 15.4 billion by 2026 from USD 8.3 billion in 2021 at a CAGR of 13.3%. Increasing operational costs and regulatory requirements associated with clinical research studies, government grants to support clinical trials, and growing R&D expenditure on drug development by pharma-biotech...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.